.Pharmacolibrary.Drugs.ATC.D.D11AH07 .Pharmacolibrary.Drugs.ATC.D.D11AH07| name: | Tralokinumab |
| ATC code: | D11AH07 | route: | subcutaneous |
| n-compartments | 2 |
Tralokinumab is a human monoclonal antibody that specifically binds to and inhibits interleukin-13 (IL-13). It is used primarily for the treatment of moderate-to-severe atopic dermatitis in adults and has received approval in several regions including the US and EU.
Pharmacokinetic parameters in adult patients with moderate to severe atopic dermatitis after subcutaneous administration; population includes both males and females, no specific comorbidity, typical adult weight.
Soehoel, A, et al., & Timmermann, S (2022). Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis. Clinical pharmacology in drug development 11(8) 910–921. DOI:10.1002/cpdd.1113 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35671038
Baverel, PG, et al., & Kuna, P (2015). Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. British journal of clinical pharmacology 80(6) 1337–1349. DOI:10.1111/bcp.12725 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26182954
Baverel, P, et al., & Gevorkyan, H (2018). A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug metabolism and pharmacokinetics 33(3) 150–158. DOI:10.1016/j.dmpk.2017.12.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29622380